NewAmsterdam Pharma Company N.V.(NAMS:US)
Market Cap$2.333B
Key Metrics
Price$19.83
Revenue (TTM)$7.12M
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$259.5M
EBITDA (TTM)-$204.42M
Op. Margin (TTM)-3.43K%
Dividend Yield-
Holders Yield-
Cash on hand$424.15M
Total Assets$704.45M
Net Assets$631.42M
Total Debt$82K
Key Metrics
Price$19.83
Revenue (TTM)$7.12M
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$259.5M
EBITDA (TTM)-$204.42M
Op. Margin (TTM)-3.43K%
Dividend Yield-
Holders Yield-
Cash on hand$424.15M
Total Assets$704.45M
Net Assets$631.42M
Total Debt$82K
Financials
| Name | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $3.7M | $3.04M | $32K | $348K | $19.15M | $2.98M | $12.77M | $29.11M | $2.28M | $1.4M | $803K | $2.94M | $1.72M | $8.63M |
Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| $68.57M | $61.46M | $66.01M | $55.49M | $54.78M | $71.9M | $59.21M | $52.98M | $53.68M | $55.99M | $50M | $51.22M | $40.72M | $47.26M | |
| Research and Development | $41.67M | $38.01M | $38.59M | $30.97M | $27.52M | $44.75M | $34.9M | $35.7M | $38.38M | $42.43M | $41.29M | $43.37M | $34.34M | $40.42M |
| Selling, General, and Administrative | $26.89M | $23.45M | $27.42M | $24.52M | $27.26M | $27.15M | $24.31M | $17.28M | $15.3M | $13.56M | $8.71M | $7.85M | $6.38M | $6.84M |
| Other Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | -$64.86M | -$58.42M | -$65.98M | -$55.14M | -$35.64M | -$68.93M | -$46.43M | -$23.87M | -$51.4M | -$54.59M | -$49.2M | -$48.28M | -$39M | -$38.63M |
| $729K | $9.98M | -$8.94M | -$16.86M | $18.27M | $29.4M | -$48.95M | $8.36M | $13.57M | -$38.29M | $1.61M | $2.43M | $4.19M | -$2.17M | |
| Non-Operating Interest Income | $5.81M | $5.65M | $6.47M | $6.71M | $7.06M | $7.35M | $4.49M | $4.44M | $4.87M | $3.08M | $2.67M | $3.06M | $4.61M | $943K |
| Non-Operating Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Income/Expense | -$5.08M | $4.33M | -$15.42M | -$23.58M | $11.22M | $22.05M | -$53.43M | $3.91M | $8.7M | -$41.37M | -$1.06M | -$634K | -$422K | -$3.11M |
Income Before Tax | -$64.14M | -$48.44M | -$74.92M | -$72.01M | -$17.36M | -$39.53M | -$92.18M | -$16.65M | -$39.01M | -$93.77M | -$49.47M | -$47.13M | -$38.29M | -$42.02M |
Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1K | $0 | $0 | $27K | $0 | $0 | $0 |
Net Income | -$64.14M | -$48.44M | -$74.92M | -$72.01M | -$17.36M | -$39.53M | -$92.18M | -$16.65M | -$39.01M | -$93.77M | -$49.5M | -$47.13M | -$38.29M | -$42.02M |
Minority Interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -$64.14M | -$48.44M | -$74.92M | -$72.01M | -$17.36M | -$39.53M | -$92.18M | -$16.65M | -$39.01M | -$93.77M | -$49.5M | -$47.13M | -$38.29M | -$42.02M |
Shares Outstanding (Basic) | 117.65M | 121.72M | - | 119M | 112.51M | 116.12M | - | 94.75M | 94.71M | 88.38M | - | 82.47M | 82.06M | 81.63M |
Shares Outstanding (Diluted) | 117.65M | 121.72M | - | 119M | 112.51M | 116.12M | - | 94.75M | 94.71M | 88.38M | - | 82.47M | 82.06M | 81.63M |
EPS (Basic) | -$0.55 | -$0.40 | - | -$0.61 | -$0.15 | -$0.34 | - | -$0.18 | -$0.41 | -$1.06 | - | -$0.57 | -$0.47 | -$0.51 |
EPS (Diluted) | -$0.55 | -$0.40 | - | -$0.61 | -$0.15 | -$0.34 | - | -$0.18 | -$0.41 | -$1.06 | - | -$0.57 | -$0.47 | -$0.51 |
EBIT | -$64.86M | -$58.42M | -$65.98M | -$55.14M | -$35.64M | -$68.93M | -$111.74M | -$23.87M | -$51.4M | -$54.59M | -$51M | -$48.28M | -$39M | -$38.63M |
EBITDA | -$59.72M | -$62.69M | -$50.51M | -$31.5M | -$46.81M | -$90.92M | -$58.26M | -$27.75M | -$60.08M | -$13.21M | -$49.93M | -$47.64M | -$38.56M | -$35.51M |